Advertisement

Topics

PubMed Journals Articles About "Damon Runyon Cancer Research Foundation" RSS

12:40 EST 17th November 2018 | BioPortfolio

Damon Runyon Cancer Research Foundation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Damon Runyon Cancer Research Foundation articles that have been published worldwide.

More Information about "Damon Runyon Cancer Research Foundation" on BioPortfolio

We have published hundreds of Damon Runyon Cancer Research Foundation news stories on BioPortfolio along with dozens of Damon Runyon Cancer Research Foundation Clinical Trials and PubMed Articles about Damon Runyon Cancer Research Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Damon Runyon Cancer Research Foundation Companies in our database. You can also find out about relevant Damon Runyon Cancer Research Foundation Drugs and Medications on this site too.

Showing "Damon Runyon Cancer Research Foundation" PubMed Articles 1–25 of 38,000+

Clinical research for non-extraction treatment of maxillary mild-to-moderate crowding with Damon technology .

To compare the clinical efficacy of non-extraction treatment in maxillary mild-to-moderate crowding cases with Damon self-ligating system and Roth traditional brackets.


Research progress of circular RNAs in lung cancer.

Lung cancer is one of the most common cancers and the leading cause of cancer-related death worldwide. Despite encouraging results achieved with targeted therapy in recent years, the early diagnosis and treatment of lung cancer remains a major problem. Circular RNA (circRNA), a type of RNA with covalently closed continuous loop structures, has structural stability and certain tissue specificity. Recent studies have found that circRNAs have an important role in tumor development and are expected to be reveal...

The Partnership for Accelerating Cancer Therapies.

As a part of the Cancer Moonshot, the National Cancer Institute, part of the National Institutes of Health, the Foundation for National Institutes of Health, the US Food and Drug Administration, and 12 pharmaceutical companies have formed a 5-year, $220 million precompetitive public-private research collaboration called the Partnership for Accelerating Cancer Therapies. A systematic cross-sector effort to identify and develop robust, standardized biomarkers and related clinical data, Partnership for Acceler...


The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer.

Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with breast cancer upon treatment initiation.

The Florence Nightingale Foundation: developing nursing's leaders.

Ursula Ward, Chief Executive, Florence Nightingale Foundation, chiefexec@florence-nightingale-foundation.org.uk , describes the role of the foundation and its plans for the future.

Promoting scientist-advocate collaborations in cancer research: why and how.

Advocates bring unique and important viewpoints to the cancer research process, ensuring that scientific and medical advances are patient-centered and relevant. In this article, we discuss the benefits of engaging advocates in cancer research and underscore ways in which both the scientific and patient communities can facilitate this mutually beneficial collaboration. We discuss how to establish and nurture successful scientist-advocate relationships throughout the research process. We review opportunities ...

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Cancer research is an essential part of national cancer control programmes, and the emerging economies of Central and Eastern Europe (CEE) and the Russian Federation and Central Asia (R-CA) (Commonwealth of Independent States) remain relatively understudied. Here, we map the cancer research activity from the 29 countries across these regions over a 10-year period (2007-2016), using a standard scientometric approach. Research activity was compared with the countries' wealth and with the disease burden from ...

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Translational cancer research covers the whole cancer research continuum from basic to preclinical to early clinical, late clinical and outcomes research. Basic-preclinical research is the "engine" for early clinical research bridging the early translational research gap. Cancer Core Europe has been created to construct a sustainable, high level, shared research infrastructure platform with research collaborations and taskforces (data sharing, clinical trials, genomics, immunotherapy, imaging, legal & ethic...

Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.

The long-term impact of hormone therapy for breast cancer on risk of osteoporosis and the extent to which bone screening recommendations are implemented in daily practice remain unknown. We found that the aromatase inhibitor-induced risk of osteoporosis did not continue in the off-treatment follow-up. Adherence to screening recommendations was suboptimal.

A scoping review of trials of interventions led or delivered by cancer nurses.

Advances in research and technology coupled with an increased cancer incidence and prevalence have resulted in significant expansion of cancer nurse role, in order to meet the growing demands and expectations of people affected by cancer (PABC). Cancer nurses are also tasked with delivering an increasing number of complex interventions as a result of ongoing clinical trials in cancer research. However much of this innovation is undocumented, and we have little insight about the nature of novel interventions...

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

The Institute of Medicine has called for approaches to help maximize the return on investments (ROI) in cancer clinical trials. Value of Research (VOR) is a health economics technique that estimates ROI and can inform research prioritization. Our objective was to evaluate the impact of using VOR analyses on the clinical trial proposal review process within the SWOG cancer clinical trials consortium.

Eduardo "Eddie" Méndez: In Memoriam (1972-2018).

Strategies used and lessons learned by community assistants in organising regional forums for cancer education in Iowa, USA.

Cancer prevention efforts at the community level are essential in the fight against cancer. Understanding community dynamics provides insights into building meaningful relationships between researchers and community organizations. In this study, community assistants were hired to organize and host forums to encourage interdisciplinary collaboration, with the goal of strengthening and transforming relationships between a university academic health center and communities. A 19-item questionnaire was developed...

Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

Comprehensive analysis of differentially expressed non-coding RNAs and mRNAs in gastric cancer cells under hypoxic conditions.

Hypoxia commonly occurs in solid cancers, especially in gastric cancer due to its rapid growth. The ability of gastric cancer cells to survive and progress under hypoxic conditions has been known for decades, but the mechanisms underlying this characteristic remain poorly understood. As cancer cells undergo changes in their genetic profile under certain conditions, we investigated the expression profile of non-coding RNAs (circRNAs, lncRNAs, and miRNAs) and mRNAs in gastric cancer MKN-28 cells under hypoxic...

European Academy of Cancer Sciences - position paper.

The European Academy of Cancer Sciences (EACS) is an independent advisory body of well-recognised medical specialists and researchers striving to create a compelling interactive continuum of cancer research, from innovative basic research to implementation of state-of-the-art evidence-based cancer care and prevention. Achieving the above will entail bridging high-quality basic and preclinical cancer research to research on prevention, early detection and therapeutics as well as improving coordination of tra...

New Foundation Revives Debate About Health Research Funded by Big Tobacco.

Cancer-free aging: insights from Spalax ehrenbergi superspecies.

Cancer and ageing can be regarded as two different manifestations of the same underlying process-accumulation of cellular damage-and therefore both are closely linked. Nowadays, the ageing of populations worldwide is leading to an unprecedented increase in cancer cases and fatalities, and therefore the understanding of links between cancer and ageing is more important than ever. Spalax is considered an excellent model for ageing and, additionally, for cancer research, due to not show clear age-related pheno...

Foundation Funding To Research And Improve Medicaid.

Non-participation in breast cancer screening among previous cancer patients.

Breast cancer can be detected at early stages through organised screening. This study explored reasons for non-participation in breast cancer screening among previous cancer patients, who have high risk of developing a new primary cancer.

Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer.

Quality-of-life (QOL) has been reported to affect the prognosis of many types of cancer, and several studies used various QOL assessment tools to determine the relationship between QOL and cancer prognosis. In this study, QOL-Questionnaire for Cancer Patients Treated with Anti-Cancer Drugs-the Breast (QOL-ACD-B) was modified to be suitable for preoperative chemotherapy (POC) and was named the QOL-ACD-BP.

A paradigm shift for prostate cancer diagnostics.

The current praxis of diagnosing prostate cancer, with systematic prostate biopsies in men with raised serum prostate-specific antigen (PSA) levels, leads to considerable over-diagnosis and over-treatment of indolent cancer. Recent research has opened up for a paradigm shift to risk stratified, sequential and targeted prostate cancer diagnostics, which will reduce over-diagnosis. Sweden now moves towards organised PSA testing for those men who, after proper counselling, wish to be tested. Organised PSA test...

Correlates of smoking status in cancer survivors.

To determine the characteristics associated with cancer survivors which indicate continued cigarette smoking at or around the time of cancer diagnosis.

Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.

Cancer stem-like cells (CSCs) contribute to the progression and androgen deprivation therapy (ADT) resistance of prostate cancer. Since CSCs depend on their specific niche, including tumor-associated macrophages (TAMs), elucidating the network between CSCs and TAMs may help to effectively inhibit the progression and ADT resistance of prostate cancer.

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy.

Elevated glycolysis remains a universal and primary character of cancer metabolism, which deeply depends on dysregulated metabolic enzymes. Lactate dehydrogenase A (LDHA) facilitates glycolytic process by converting pyruvate to lactate. Numerous researches demonstrate LDHA has an aberrantly high expression in multiple cancers, which is associated with malignant progression. In this review, we summarized LDHA function in cancer research. First, we gave an introduction of structure, location, and basic functi...


Advertisement
Quick Search
Advertisement
Advertisement